Prometheus Biosciences, Inc.

Prometheus Biosciences, Inc. is a clinical-stage biotechnology company that is revolutionizing medicine with precision. The company, founded in 1995, is listed on Nasdaq under the ticker symbol RXDX. Prometheus Biosciences is pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. The company's precision medicine platform, Prometheus360™, utilizes proprietary machine learning-based analytical approaches and one of the world's largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. The company's innovative approach sets it apart in the biotechnology and pharmaceutical industries. In December 2022, Prometheus Biosciences received a significant $500.00M Post-IPO Equity investment, demonstrating confidence from the investor community. Additionally, the recognition as one of the Best Places to Work by Biospace in 2022 underscores the company's commitment to creating a positive and fulfilling work environment. Headquartered in San Diego, CA, Prometheus Biosciences, Inc. is strategically positioned within a hub of biotechnology and innovation.